Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial-Reference-Cited by-同舟云学术

Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

Published:2014-07 Issue:7 Volume:109 Page:1055-1064
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Steenholdt Casper,Bendtzen Klaus,Brynskov Jørn,Thomsen Ole Ø,Ainsworth Mark A

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2014106.pdf

Reference34 articles.

1. Management of Crohns disease in adults.;Lichtenstein;Am J Gastroenterol,2009

2. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.;Ford;Am J Gastroenterol,2011

3. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: Current management.;Dignass;J Crohns Colitis,2010

4. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohns and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?;DHaens;Am J Gastroenterol,2011

5. Guidelines for the management of inflammatory bowel disease in adults.;Mowat;Gut,2011

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

2. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

3. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory;Therapeutic Drug Monitoring;2024-04-09

4. A Crohn-betegég terápiás stratégiája;Orvosi Hetilap;2024-03-12

5. Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development;Antibodies;2024-02-26